Optimizing oral iron dosing strategies for better absorption
Optimizing Dosing Strategies in Oral Iron Supplementation
This study is testing if taking oral iron every day or every other day in a higher dose can help people with iron deficiency absorb more iron and feel better faster.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Luzerner Kantonsspital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Luzern) |
| Trial ID | NCT06238895 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates whether changing the dosing strategy of oral iron supplementation can improve iron absorption and expedite treatment for patients with iron deficiency. Participants will be divided into two groups: one receiving oral iron every day at the standard dose and the other receiving it every second day at double the standard dose. The primary outcome will be measured by the change in hemoglobin levels after 12 weeks of treatment. Participants will attend three visits throughout the study to monitor their progress.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with confirmed iron deficiency and specific hemoglobin levels.
Not a fit: Patients who have received iron supplementation within the last 12 weeks or have contraindications to the intervention will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective and faster treatment options for patients with iron deficiency anemia.
How similar studies have performed: Other studies have explored dosing strategies in iron supplementation, but this specific approach is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed Consent signed by the subject * ≥18 years of age * Iron deficiency: Ferritin \<30 µg/l * hemoglobin ≥ 80 g/l * CRP \< 5 mg/l Exclusion Criteria: * Refusal of study participation, * Regular administration of Erythropoietin * Oral or intravenous iron supplementation \<12 weeks prior to investigation * Contraindications to intervention medication (Tardyferon), e.g. known hypersensitivity or allergy to iron sulfate / ferrous sulfate * Blood transfusion or donation \<12 weeks prior to investigation * Active chemotherapy * Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject. Note Due to slow recruitment, the following inclusion criterion was removed on 09/25/2024 (MM/DD/YYYY): Anemia (as defined by the WHO): Hemoglobin \<130 g/L for men, Hemoglobin \<120 g/l for women, Hemoglobin \<110 g/l for pregnant women
Where this trial is running
Luzern
- Luzerner Kantonsspital — Luzern, Switzerland (Recruiting)
Study contacts
- Study coordinator: Meyer
- Email: eisenstudie@luks.ch
- Phone: +41 41 205 11 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.